Private company

INVIVO THERAPEUTICS HOLDINGS CORP.

American surgical and medical instruments and apparatus company2

In its 2023 annual report the company says: “We are a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries, or SCIs. Our approach to treating acute SCIs is based on our investigational Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord and is intended to treat acute SCI.”60 It is headquartered in Cambridge, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersCambridge, United States2
  • Incorporated inNV3
  • Business addressOne Kendall Square, Building 1400 East 4Th Floor, Cambridge, Ma 021393
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300FGLYJVWKVH3W382
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporate Filing Solutions, LLC, 89502 Reno, United States2
  • Registered withBusiness Center (Secretary of State), C7829-20032

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$10.7M in 2022−56% since 2016
-$30.0M-$20.0M-$10.0M02016: -$24.1M-$24.1M20162017: -$24.6M-$24.6M2017+2%2018: -$12.8M-$12.8M2018−48%2019: -$11.5M-$11.5M2019−10%2020: -$9.1M-$9.1M2020−21%2021: -$9.9M-$9.9M2021+9%2022: -$10.7M-$10.7M2022+8%
Net income456789-$10.5M in 2022−55% since 2016
-$30.0M-$20.0M-$10.0M02016: -$23.4M-$23.4M20162017: -$26.7M-$26.7M2017+14%2018: -$23.4M-$23.4M2018−12%2019: -$11.8M-$11.8M2019−49%2020: -$9.1M-$9.1M2020−23%2021: -$9.9M-$9.9M2021+9%2022: -$10.5M-$10.5M2022+6%
Fiscal year20162017201820192020202120222023
Research and development$12.6M4$11.1M5$4.9M6$5.6M7$3.9M8$4.4M9$5.2M9
Operating expenses$9.9M9$10.7M9
Operating income-$24.1M4-$24.6M5-$12.8M6-$11.5M7-$9.1M8-$9.9M9-$10.7M9
Interest$155.0K4$74.0K4
Income tax$04$05$06$07$08$09$09
Net income-$23.4M4-$26.7M5-$23.4M6-$11.8M7-$9.1M8-$9.9M9-$10.5M9
Earnings per share-$1.318-$7.489-$6.839
Earnings per share (diluted)-$1.318-$7.489-$6.839
Shares (weighted, basic)1.3M shares91.5M shares9
Shares (weighted, diluted)1.3M shares91.5M shares9

Compare INVIVO THERAPEUTICS HOLDINGS CORP. with another company

Corporate structure

INVIVO THERAPEUTICS HOLDINGS CORP. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of INVIVO THERAPEUTICS HOLDINGS CORP.

  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on INVIVO THERAPEUTICS HOLDINGS CORP., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Lind Global Fund II LP Filed SC 13G/A on INVIVO THERAPEUTICS HOLDINGS CORP., latest Feb 13, 2024
  • Brice Foose Filed SC 13G/A on INVIVO THERAPEUTICS HOLDINGS CORP., latest Feb 6, 2024 (2 filings since Apr 25, 2023)
  • Lind Global Macro Fund LP Filed SC 13G/A on INVIVO THERAPEUTICS HOLDINGS CORP., latest Feb 13, 2023 (2 filings since Feb 9, 2022)
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on INVIVO THERAPEUTICS HOLDINGS CORP., latest Feb 11, 2022
  • INVIVO THERAPEUTICS HOLDINGS CORP. Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What INVIVO THERAPEUTICS HOLDINGS CORP. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$863.0K9 Dec 31, 2022$703.0K9 Dec 31, 2021+22.8%
Accumulated depreciation$636.0K9 Dec 31, 2022$576.0K9 Dec 31, 2021+10.4%
Property and equipment, net$227.0K9 Dec 31, 2022$127.0K9 Dec 31, 2021+78.7%
Operating-lease assets (leased space)$844.0K9 Dec 31, 2022$1.2M9 Dec 31, 2021−31.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$16.4M9 Dec 31, 2022$19.0M9 Dec 31, 2021−14.1%

Leadership

Who has led INVIVO THERAPEUTICS HOLDINGS CORP., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Peter A. Reichard2006
  2. Francis Reynolds2010–2013
  3. Michael J. Astrue2013–2014
  4. Mark D. Perrin2014–2017
  5. Richard M. Toselli2022

President

  1. Peter A. Reichard2006

Chief financial officer

  1. Francis Reynolds2011–2013
  2. Gregory D. Perry2013–2014
  3. Steven F. McAllister2014–2016
  4. Melanie Golarz2017
  5. Christopher McNulty2017
  6. Richard Christopher2019–2022
2010201520202025
Board members and other officers (23)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorRichard Ann Roberts named Oct 14, 202242
  • DirectorRobert Ann Rosenthal named Oct 14, 202242

Former names

  • Design Source, Inc.Jun 4, 2004 to Oct 5, 20103

Timeline

  1. Feb 6, 20248-K Listing notice or transfer43
  2. Feb 1, 20248-K Bankruptcy or receivership44
  3. Jan 3, 20248-K Shareholder vote45
  4. Dec 1, 20238-K Listing notice or transfer46
  5. Nov 30, 20238-K Director nominations47
  6. Nov 22, 20238-K Executive or director change48
  7. Sep 1, 20238-K Ended a material agreement49
  8. Mar 9, 20238-K Other events50
  9. Nov 21, 2022New chief executive Richard M. Toselli becomes CEO12
  10. Nov 18, 20228-K Executive or director change51
  11. Oct 11, 20228-K Entered a material agreement; Unregistered sale of shares52
  12. Sep 13, 20228-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed53
  13. Jul 12, 20228-K Executive or director change54
  14. Jan 9, 2014New chief executive Mark D. Perrin becomes CEO13
  15. Sep 3, 2013New chief executive Michael J. Astrue becomes CEO14
  16. Nov 1, 2010New chief executive Francis Reynolds becomes CEO15
  17. Jun 30, 2006New chief executive Peter A. Reichard becomes CEO16

Filings

74 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 19 major events, 13 insider forms, 8 large holders, 1 private raises, 24 other. The latest 20:

  1. Mar 21, 202425-NSE EDGAR
  2. Feb 14, 2024SC 13G/A EDGAR
  3. Feb 13, 2024SC 13G/A EDGAR
  4. Feb 7, 20244/A PRIMARY DOCUMENT EDGAR
  5. Feb 7, 20244 PRIMARY DOCUMENT EDGAR
  6. Feb 6, 20248-K EDGAR
  7. Feb 6, 2024SC 13G/A BRICE FOOSE EDGAR
  8. Feb 1, 20248-K EDGAR
  9. Jan 3, 20248-K EDGAR
  10. Dec 5, 2023ARS EDGAR
  11. Dec 5, 2023DEF 14A EDGAR
  12. Dec 1, 20238-K EDGAR
  13. Nov 30, 20238-K EDGAR
  14. Nov 22, 20238-K EDGAR
  15. Nov 8, 202310-Q EDGAR
  16. Sep 1, 20238-K EDGAR
  17. Aug 9, 202310-Q EDGAR
  18. May 12, 202310-Q EDGAR
  19. Apr 25, 2023SC 13G BRICE FOOSE EDGAR
  20. Apr 24, 20233 PRIMARY DOCUMENT EDGAR

The 74 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 2 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 6, 2023Foose Brice10% ownerSale164,000$0.46$75.5KForm 4
Feb 6, 2023Foose Brice10% ownerBuy164,000$0.46$75.5KForm 4
Feb 5, 2023Foose Brice10% ownerSale166,000$0.29$47.6KForm 4
Feb 5, 2023Foose Brice10% ownerBuy166,000$0.29$47.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 11, 2022Raised $6.2 million in a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How INVIVO THERAPEUTICS HOLDINGS CORP. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARINVIVO THERAPEUTICS HOLDINGS CORP.1
  • CIK0001292519
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNevada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business addressOne Kendall Square, Building 1400 East 4Th Floor, Cambridge, MA 021391
  • Phone617-863-55241
  • Shares outstanding3,105,446 as of Nov 3, 202311
  • Public float$5.6M as of Jun 30, 20229
  • On EDGAR sinceJun 4, 20041
  • Filings883 in all: 4 (274), 8-K (175), 424B3 (53), 10-Q (47), 3 (34), UPLOAD (34), CORRESP (24), SC 13G/A (20)1
    All 52 form types

    EFFECT (18), SC 13G (17), 10-K (15), DEF 14A (14), S-8 (13), 424B5 (12), DEFA14A (9), PRE 14A (9), S-1/A (9), S-1 (8), 10QSB (7), 5 (7), 10-K/A (6), 4/A (6), S-3 (6), SB-2/A (6), SC 13D/A (6), 8-K/A (5), 424B4 (4), ARS (4), POS AM (4), SC TO-I/A (4), 10-Q/A (3), 10KSB (3), D (3), PRER14A (2), S-3/A (2), S-8 POS (2), SB-2 (2), SC 13D (2), 25-NSE (1), 8-A12B (1), 8-A12G (1), CERTNAS (1), D/A (1), FWP (1), NO ACT (1), NT 10-K (1), NT 10-Q (1), POS EX (1), REGDEX (1), S-1MEF (1), SC 14F1 (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2023
    Quarterly report (10-Q) Nov 8, 2023
    Proxy statement (DEF 14A) Dec 5, 2023
    Latest 8-K (8-K) Feb 6, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60